Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?
Số trang: 9
Loại file: pdf
Dung lượng: 876.64 KB
Lượt xem: 11
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Immune checkpoint inhibitors (ICIs) has shown remarkable benefit in the treatment of a range of cancer types, although it may initiate immune related adverse events (irAEs) in patients.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Gastric cancer Immune-related adverse events Immune checkpoint inhibitors Anti-PD-1 antibodyTài liệu có liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 179 0 0 -
6 trang 171 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 150 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 136 0 0 -
12 trang 103 0 0
-
19 trang 81 0 0
-
17 trang 71 0 0
-
9 trang 48 0 0
-
9 trang 43 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 43 0 0